This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Petri, M Search for Related Content PubMed PubMed Citation Articles by Petri, M Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CYCLOPHOSPHAMIDE Medline Plus Health Information Lupus Social Bookmarking                   What's this?

Cyclophosphamide: new approaches for systemic lupus erythematosus

Johns Hopkins University School of Medicine, Baltimore, MD, USA, mpetri{at}jhmi.edu

Cyclophosphamideremains the ‘gold standard’treatment for severe organ threatening systemic lupus erythematosus (SLE), especially renal and central nervous system lupus. Intravenous and oral cyclophosphamide have been compared, retrospectively, with similar two year remission rates of 73% and 90%.¹ In a meta-analysis, intravenous cyclophosphamide with oral prednisone is more effective than oral prednisone alone.² The efficacy of cyclophosphamidein lupus nephritis has been proven in multiple clinical trials, but efficacy has to be balanced with toxicity, including infection, gonadalfailure, and malignancy. Although the continued use of cyclophosphamidefor renal lupus has been challenged by a recent trial of mycophenolate mofetil, and may be challenged in the future by planned trials of biologics, it continues to be widely used. This review will touch on the traditional intravenous ‘pulse’ cyclophosphamide regimen, consider its toxicity, and contrast it with newer approaches to cyclophosphamide.

Key Words: cyclophosphamide • SLE

Lupus, Vol. 13, No. 5, 366-371 (2004)
DOI: 10.1191/0961203303lu1028oa


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				G. B. Appel, G. Contreras, M. A. Dooley, E. M. Ginzler, D. Isenberg, D. Jayne, L.-S. Li, E. Mysler, J. Sanchez-Guerrero, N. Solomons, et al. Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis J. Am. Soc. Nephrol., May 1, 2009; 20(5): 1103 - 1112. [Abstract] [Full Text] [PDF]

				K. M. Antoniou, G. Margaritopoulos, F. Economidou, and N. M. Siafakas Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement Eur. Respir. J., April 1, 2009; 33(4): 882 - 896. [Abstract] [Full Text] [PDF]

				C Nannini, C. Crowson, E. Matteson, and K. Moder Mycophenolate mofetil is effective in reducing disease flares in systemic lupus erythematosus patients: a retrospective study Lupus, April 1, 2009; 18(5): 394 - 399. [Abstract] [PDF]

				A. Sinclair, G. Appel, M.A. Dooley, E. Ginzler, D. Isenberg, D. Jayne, D. Wofsy, and N. Solomons Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS) Lupus, December 1, 2007; 16(12): 972 - 980. [Abstract] [PDF]

				M. Tokunaga, K. Saito, D. Kawabata, Y. Imura, T. Fujii, S. Nakayamada, S. Tsujimura, M. Nawata, S. Iwata, T. Azuma, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system Ann Rheum Dis, April 1, 2007; 66(4): 470 - 475. [Abstract] [Full Text] [PDF]

				G H Stummvoll, M Aringer, J S Smolen, S Schmaldienst, E Jimenez-Boj, W H Horl, W B Graninger, and K Derfler IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study Ann Rheum Dis, July 1, 2005; 64(7): 1015 - 1021. [Abstract] [Full Text] [PDF]

				D. M. Fine Pharmacological Therapy of Lupus Nephritis JAMA, June 22, 2005; 293(24): 3053 - 3060. [Abstract] [Full Text] [PDF]